3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Identifieur interne : 000732 ( PubMed/Corpus ); précédent : 000731; suivant : 0007333D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
Auteurs : T I Opera ; C L Waller ; G R MarshallSource :
- Drug design and discovery [ 1055-9612 ] ; 1994.
English descriptors
- KwdEn :
- Binding Sites, Chemistry, Physical (methods), Drug Design, HIV Protease Inhibitors (chemistry), HIV Protease Inhibitors (metabolism), HIV Protease Inhibitors (pharmacology), HIV-1 (enzymology), Models, Molecular, Molecular Conformation, Protein Binding, Protein Conformation, Structure-Activity Relationship.
- MESH :
- chemical , chemistry : HIV Protease Inhibitors.
- chemical , metabolism : HIV Protease Inhibitors.
- enzymology : HIV-1.
- methods : Chemistry, Physical.
- chemical , pharmacology : HIV Protease Inhibitors.
- Binding Sites, Drug Design, Models, Molecular, Molecular Conformation, Protein Binding, Protein Conformation, Structure-Activity Relationship.
Abstract
Comparative Molecular Field Analysis (CoMFA), a three-dimensional quantitative structure-activity relationship (3D-QSAR) paradigm (Cramer, R.D.; et al. (1988), J. Am. Chem. Soc., 110, 5959-5967), correlates variations in the (experimental) biological activity with 3D variance in the steric and electrostatic field of modeled compounds. Of general interest to the drug design area is the interpretation of CoMFA results, in order to gain maximum benefit from an established 3D-QSAR model. CoMFA studies report results using the standard deviation (stdev) times(*) coefficient (beta) field and its contributions to make SAR statements. This field is the scalar product of the absolute stdev of the CoMFA field at a lattice point and the QSAR equation coefficient (beta) at the same point. Negative beta values yield detrimental contributions, while positive beta values are considered beneficial. The QSAR equation is based on actual field values, therefore both positive and negative field values can have beneficial effect to the target property (Y), depending on the sign of beta. The results of a CoMFA model on 59 HIV-1 protease (HIV-PR) inhibitors (Waller, C.L.; et al. (1993), J. Med. Chem., 36, 4152-4160) were compared with the HIV-PR crystal structure to analyze the correspondence between CoMFA fields and ligand binding regions in the enzyme. Local steric and electrostatic interactions were analyzed in terms of various field values and beta coefficients. While redundant for some regions, other field contours besides stdev* beta bring additional information. Using this method, we observed a unique region with negative beta values for the electrostatic field (based on a -1 charged probe) located opposite of the scissile bond, between P1 and P1', where steric stdev* beta values are positive. Four hydrophobic residues in the HIV-PR crystal delimit the region, which is suggested as a new potential hydrophobic binding site for the inhibitors. The same region was confirmed using the stdev* beta contours of a HINT (Kellogg, G.; et al. (1991), J. Comput.-Aided Mol. Design, 5, 545-552) calculation on the same model. The steric, electrostatic and lipophilic fields of the CoMFA and HINT models are presented in various forms, and the information extracted is detailed.
PubMed: 7578806
Links to Exploration step
pubmed:7578806Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.</title><author><name sortKey="Opera, T I" sort="Opera, T I" uniqKey="Opera T" first="T I" last="Opera">T I Opera</name><affiliation><nlm:affiliation>Center for Molecular Design, Washington University School of Medicine, St. Louis, MO 63130, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Waller, C L" sort="Waller, C L" uniqKey="Waller C" first="C L" last="Waller">C L Waller</name></author><author><name sortKey="Marshall, G R" sort="Marshall, G R" uniqKey="Marshall G" first="G R" last="Marshall">G R Marshall</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1994">1994</date><idno type="RBID">pubmed:7578806</idno><idno type="pmid">7578806</idno><idno type="wicri:Area/PubMed/Corpus">000732</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.</title><author><name sortKey="Opera, T I" sort="Opera, T I" uniqKey="Opera T" first="T I" last="Opera">T I Opera</name><affiliation><nlm:affiliation>Center for Molecular Design, Washington University School of Medicine, St. Louis, MO 63130, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Waller, C L" sort="Waller, C L" uniqKey="Waller C" first="C L" last="Waller">C L Waller</name></author><author><name sortKey="Marshall, G R" sort="Marshall, G R" uniqKey="Marshall G" first="G R" last="Marshall">G R Marshall</name></author></analytic><series><title level="j">Drug design and discovery</title><idno type="ISSN">1055-9612</idno><imprint><date when="1994" type="published">1994</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Binding Sites</term><term>Chemistry, Physical (methods)</term><term>Drug Design</term><term>HIV Protease Inhibitors (chemistry)</term><term>HIV Protease Inhibitors (metabolism)</term><term>HIV Protease Inhibitors (pharmacology)</term><term>HIV-1 (enzymology)</term><term>Models, Molecular</term><term>Molecular Conformation</term><term>Protein Binding</term><term>Protein Conformation</term><term>Structure-Activity Relationship</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" qualifier="enzymology" xml:lang="en"><term>HIV-1</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemistry, Physical</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Binding Sites</term><term>Drug Design</term><term>Models, Molecular</term><term>Molecular Conformation</term><term>Protein Binding</term><term>Protein Conformation</term><term>Structure-Activity Relationship</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Comparative Molecular Field Analysis (CoMFA), a three-dimensional quantitative structure-activity relationship (3D-QSAR) paradigm (Cramer, R.D.; et al. (1988), J. Am. Chem. Soc., 110, 5959-5967), correlates variations in the (experimental) biological activity with 3D variance in the steric and electrostatic field of modeled compounds. Of general interest to the drug design area is the interpretation of CoMFA results, in order to gain maximum benefit from an established 3D-QSAR model. CoMFA studies report results using the standard deviation (stdev) times(*) coefficient (beta) field and its contributions to make SAR statements. This field is the scalar product of the absolute stdev of the CoMFA field at a lattice point and the QSAR equation coefficient (beta) at the same point. Negative beta values yield detrimental contributions, while positive beta values are considered beneficial. The QSAR equation is based on actual field values, therefore both positive and negative field values can have beneficial effect to the target property (Y), depending on the sign of beta. The results of a CoMFA model on 59 HIV-1 protease (HIV-PR) inhibitors (Waller, C.L.; et al. (1993), J. Med. Chem., 36, 4152-4160) were compared with the HIV-PR crystal structure to analyze the correspondence between CoMFA fields and ligand binding regions in the enzyme. Local steric and electrostatic interactions were analyzed in terms of various field values and beta coefficients. While redundant for some regions, other field contours besides stdev* beta bring additional information. Using this method, we observed a unique region with negative beta values for the electrostatic field (based on a -1 charged probe) located opposite of the scissile bond, between P1 and P1', where steric stdev* beta values are positive. Four hydrophobic residues in the HIV-PR crystal delimit the region, which is suggested as a new potential hydrophobic binding site for the inhibitors. The same region was confirmed using the stdev* beta contours of a HINT (Kellogg, G.; et al. (1991), J. Comput.-Aided Mol. Design, 5, 545-552) calculation on the same model. The steric, electrostatic and lipophilic fields of the CoMFA and HINT models are presented in various forms, and the information extracted is detailed.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">7578806</PMID><DateCreated><Year>1995</Year><Month>11</Month><Day>29</Day></DateCreated><DateCompleted><Year>1995</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1055-9612</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>1994</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Drug design and discovery</Title><ISOAbbreviation>Drug Des Discov</ISOAbbreviation></Journal><ArticleTitle>3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.</ArticleTitle><Pagination><MedlinePgn>29-51</MedlinePgn></Pagination><Abstract><AbstractText>Comparative Molecular Field Analysis (CoMFA), a three-dimensional quantitative structure-activity relationship (3D-QSAR) paradigm (Cramer, R.D.; et al. (1988), J. Am. Chem. Soc., 110, 5959-5967), correlates variations in the (experimental) biological activity with 3D variance in the steric and electrostatic field of modeled compounds. Of general interest to the drug design area is the interpretation of CoMFA results, in order to gain maximum benefit from an established 3D-QSAR model. CoMFA studies report results using the standard deviation (stdev) times(*) coefficient (beta) field and its contributions to make SAR statements. This field is the scalar product of the absolute stdev of the CoMFA field at a lattice point and the QSAR equation coefficient (beta) at the same point. Negative beta values yield detrimental contributions, while positive beta values are considered beneficial. The QSAR equation is based on actual field values, therefore both positive and negative field values can have beneficial effect to the target property (Y), depending on the sign of beta. The results of a CoMFA model on 59 HIV-1 protease (HIV-PR) inhibitors (Waller, C.L.; et al. (1993), J. Med. Chem., 36, 4152-4160) were compared with the HIV-PR crystal structure to analyze the correspondence between CoMFA fields and ligand binding regions in the enzyme. Local steric and electrostatic interactions were analyzed in terms of various field values and beta coefficients. While redundant for some regions, other field contours besides stdev* beta bring additional information. Using this method, we observed a unique region with negative beta values for the electrostatic field (based on a -1 charged probe) located opposite of the scissile bond, between P1 and P1', where steric stdev* beta values are positive. Four hydrophobic residues in the HIV-PR crystal delimit the region, which is suggested as a new potential hydrophobic binding site for the inhibitors. The same region was confirmed using the stdev* beta contours of a HINT (Kellogg, G.; et al. (1991), J. Comput.-Aided Mol. Design, 5, 545-552) calculation on the same model. The steric, electrostatic and lipophilic fields of the CoMFA and HINT models are presented in various forms, and the information extracted is detailed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Opera</LastName><ForeName>T I</ForeName><Initials>TI</Initials><AffiliationInfo><Affiliation>Center for Molecular Design, Washington University School of Medicine, St. Louis, MO 63130, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waller</LastName><ForeName>C L</ForeName><Initials>CL</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>G R</ForeName><Initials>GR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>SWITZERLAND</Country><MedlineTA>Drug Des Discov</MedlineTA><NlmUniqueID>9200627</NlmUniqueID><ISSNLinking>1026-7921</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D001665">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D002627">Chemistry, Physical</DescriptorName><QualifierName MajorTopicYN="N" UI="Q000379">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015195">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D017320">HIV Protease Inhibitors</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000737">chemistry</QualifierName><QualifierName MajorTopicYN="Y" UI="Q000378">metabolism</QualifierName><QualifierName MajorTopicYN="N" UI="Q000494">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D015497">HIV-1</DescriptorName><QualifierName MajorTopicYN="Y" UI="Q000201">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008958">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D008968">Molecular Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011485">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D011487">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N" UI="D013329">Structure-Activity Relationship</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7578806</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000732 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000732 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Musique
|area= OperaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:7578806
|texte= 3D-QSAR of human immunodeficiency virus (I) protease inhibitors. III. Interpretation of CoMFA results.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:7578806" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a OperaV1
| This area was generated with Dilib version V0.6.21. |  |